AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30177406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy with 50Hz frequency, low intensity of 20Gauss, combined with Conventional physical therapy Protocol
Number of subjects: 50
Study 30177406 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy Protocol
Number of subjects: 50
Study 28347663 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 205
Study 28347663 — intervention group
Group type: COMPARATOR
Intervention: Pager
Number of subjects: 205
Study 25534298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan exercise sessions (Yang style) twice a week for 12 weeks
Number of subjects: 36
Study 25534298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 36
Study 22893563 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg daily
Number of subjects: 1139
Study 22893563 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 1139
Study 22893563 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 1139
Study 22893563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 20974993 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 24
Study 20974993 — intervention group
Group type: COMPARATOR
Intervention: Gatorade (control)
Number of subjects: 24
Study 20974993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (orange juice and grapefruit juice)
Number of subjects: 24
Study 19250072 — intervention group
Group type: COMPARATOR
Intervention: Anatomical approach (group A)
Number of subjects: 97
Study 19250072 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach (group B)
Number of subjects: 97
Study 17157434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.1mg) injected submucosally at the urethrotomy site
Number of subjects: 40
Study 17157434 — intervention group
Group type: COMPARATOR
Intervention: Control group (internal urethrotomy without mitomycin C)
Number of subjects: 40
Study 15975061 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 15975061 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 15975061 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 0
Study 15975061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14613569 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (weekly subcutaneous administration)
Number of subjects: 1095
Study 9792934 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose IL-2 infusion combined with CTX-based chemotherapy
Number of subjects: 15
Study 9792934 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) alone
Number of subjects: 15
Study 9792934 — intervention group
Group type: COMPARATOR
Intervention: Triple chemotherapy (CTX, etoposide and Ara-C)
Number of subjects: 15
Study 7924128 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg daily for 12 weeks
Number of subjects: 36
Study 7924128 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10 mg daily for 12 weeks
Number of subjects: 36
Study 3131874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin
Number of subjects: 37
Study 3131874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem
Number of subjects: 37
Study 3131874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol
Number of subjects: 37
Study 3131874 — intervention group
Group type: COMPARATOR
Intervention: Normal coronary arteries
Number of subjects: 37
Study 3131874 — intervention group
Group type: COMPARATOR
Intervention: Stenotic arteries
Number of subjects: 37
Study 4885025 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphamethoxazole-trimethoprim combination (2:1 and 10:1)
Number of subjects: 154
Study 4885025 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphamethoxazole-trimethoprim combination (5:1)
Number of subjects: 154
Study 4885025 — intervention group
Group type: COMPARATOR
Intervention: ampicillin
Number of subjects: 154
Study 4885025 — intervention group
Group type: COMPARATOR
Intervention: sulphadimidine
Number of subjects: 154
Study 31930678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration (24 international units)
Number of subjects: 161
Study 31930678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 30945511 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui
Number of subjects: 36
Study 30945511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 28611340 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion for 72 hours
Number of subjects: 80
Study 28611340 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 80
Study 25848890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with Vitamin C (VIT) - 2 vitamin C tablets (1 g and 500 mg) ingested at 30 min and 1 h 30 min, respectively
Number of subjects: 11
Study 25848890 — intervention group
Group type: COMPARATOR
Intervention: Sitting without Vitamin C (SIT)
Number of subjects: 11
Study 23069326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 39
Study 21172397 — intervention group
Group type: EXPERIMENTAL
Intervention: P. freudenreichii ET‐3 culture medium (3g solid content and 283.5μg of DHNA)
Number of subjects: 25
Study 21172397 — intervention group
Group type: EXPERIMENTAL
Intervention: P. freudenreichii ET‐3 culture medium (0.267g solid content and 22.5μg of DHNA)
Number of subjects: 25
Study 21172397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unfermented product)
Number of subjects: 25
Study 19901920 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 0
Study 16697850 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (outpatient behavioral therapy)
Number of subjects: 143
Study 16697850 — intervention group
Group type: COMPARATOR
Intervention: Added video instructions with standard therapy
Number of subjects: 143
Study 16697850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uroflowmetry biofeedback with standard therapy
Number of subjects: 143
Study 16697850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uroflowmetry biofeedback with standard therapy (per protocol analysis)
Number of subjects: 143
Study 14990012 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 8
Study 14990012 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 8
Study 14990012 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 8
Study 14990012 — intervention group
Group type: COMPARATOR
Intervention: Regular aspirin use for 30-60 months
Number of subjects: 8
Study 14990012 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 8
Study 11376916 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 15
Study 11376916 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 15
Study 11376916 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.6 g/kg ethanol)
Number of subjects: 15
Study 11376916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine, 0.0 g/kg ethanol)
Number of subjects: 15
Study 11376916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone (0 mg caffeine)
Number of subjects: 15
Study 11376916 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop and CFF performance
Number of subjects: 15
Study 9400342 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (up to 60 mg/d)
Number of subjects: 84
Study 9400342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8480929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (3 doses)
Number of subjects: 102
Study 8480929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 doses)
Number of subjects: 102
Study 8480929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 doses)
Number of subjects: 102
Study 8480929 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 3079009 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron succinylprotein complex (80 mg of elemental iron daily)
Number of subjects: 40
Study 3079009 — intervention group
Group type: COMPARATOR
Intervention: Iron gluconate complex (125 mg of elemental iron daily)
Number of subjects: 40
Study 3079009 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron succinylprotein complex
Number of subjects: 40
Study 3079009 — intervention group
Group type: COMPARATOR
Intervention: Iron gluconate complex
Number of subjects: 40
Study 29272211 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 (1 g/twice daily)
Number of subjects: 41
Study 29272211 — intervention group
Group type: EXPERIMENTAL
Intervention: cranberry juice (200 ml, twice daily)
Number of subjects: 41
Study 29272211 — intervention group
Group type: EXPERIMENTAL
Intervention: cranberry juice enriched with omega‐3 (200 ml, containing 1 g omega‐3, twice daily)
Number of subjects: 41
Study 29272211 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 41
Study 28167331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dampening appraisals
Number of subjects: 43
Study 28167331 — intervention group
Group type: COMPARATOR
Intervention: Emotion-focus amplifying
Number of subjects: 43
Study 28167331 — intervention group
Group type: COMPARATOR
Intervention: Self-focus amplifying
Number of subjects: 43
Study 28167331 — intervention group
Group type: COMPARATOR
Intervention: Control instructions
Number of subjects: 43
Study 26182775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-fascial local anaesthetic (LA) inguinal field block with 20 ml 0.5% bupivacaine, 20 ml 2% lignocaine with adrenaline, 20 ml normal saline, 3 ml NaHCO3
Number of subjects: 62
Study 26182775 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anaesthesia (SA) with 0.5% Bupivacaine
Number of subjects: 62
Study 24163113 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg saxagliptin q.d.
Number of subjects: 22
Study 24163113 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg sitagliptin q.d.
Number of subjects: 22
Study 24163113 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg vildagliptin q.d.
Number of subjects: 22
Study 24163113 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg vildagliptin b.i.d.
Number of subjects: 22
Study 24163113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21970981 — intervention group
Group type: EXPERIMENTAL
Intervention: FX05 oxygenator
Number of subjects: 40
Study 21970981 — intervention group
Group type: COMPARATOR
Intervention: RX05 + arterial filter
Number of subjects: 40
Study 19160857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic prednisolone injection
Number of subjects: 73
Study 19160857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection
Number of subjects: 73
Study 19160857 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (oral administration)
Number of subjects: 73
Study 16899101 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 51
Study 16899101 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 51
Study 16281653 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT) incorporating postural drainage (PD) and vibration
Number of subjects: 20
Study 16281653 — intervention group
Group type: COMPARATOR
Intervention: Test of incremental respiratory endurance (TIRE)
Number of subjects: 20
Study 11372003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/mL aspartame
Number of subjects: 43
Study 11372003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/mL aspartame
Number of subjects: 43
Study 11372003 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg aspartame (in vivo)
Number of subjects: 43
Study 9181653 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole continuous therapy for 6 months
Number of subjects: 12
Study 9181653 — intervention group
Group type: COMPARATOR
Intervention: Albendazole discontinuous therapy for 6 courses of 4 weeks with a 2 week drug-free interval
Number of subjects: 12
Study 8215860 — intervention group
Group type: EXPERIMENTAL
Intervention: DYN 1x/wk (n = 14)
Number of subjects: 78
Study 8215860 — intervention group
Group type: EXPERIMENTAL
Intervention: DYN-IM 1x/wk (n = 16)
Number of subjects: 78
Study 8215860 — intervention group
Group type: EXPERIMENTAL
Intervention: DYN 2x/wk (n = 19)
Number of subjects: 78
Study 8215860 — intervention group
Group type: EXPERIMENTAL
Intervention: DYN-IM 2x/wk (n = 10)
Number of subjects: 78
Study 8215860 — intervention group
Group type: COMPARATOR
Intervention: CONT (n = 19)
Number of subjects: 78
Study 3327669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg, b.i.d.)
Number of subjects: 82
Study 3327669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (b.i.d.)
Number of subjects: 82
Study 3327669 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg, b.i.d.)
Number of subjects: 82
Study 31622777 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion at 1.5pmol/kg/min
Number of subjects: 10
Study 31622777 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP + GIP(3‐30)NH2 infusion
Number of subjects: 10
Study 31622777 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 10
Study 31622777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31622777 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 infusion
Number of subjects: 10
Study 31100769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay observers reviewing 2D photographs of patients with unilateral enophthalmos
Number of subjects: 60
Study 31100769 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mm difference between eyes)
Number of subjects: 60
Study 28779925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back massage
Number of subjects: 62
Study 26295732 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% nebulised hypertonic saline (HS) every ± 6 hours
Number of subjects: 317
Study 26295732 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 317
Study 26295732 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% nebulised hypertonic saline (HS)
Number of subjects: 317
Study 23628854 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 3899
Study 23628854 — intervention group
Group type: COMPARATOR
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 3899
Study 23628854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 3899
Study 20957469 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain control (group 1)
Number of subjects: 70
Study 20957469 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (group 2)
Number of subjects: 70
Study 19036078 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 231
Study 19036078 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 231
Study 17315273 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT decompression
Number of subjects: 200
Study 17315273 — intervention group
Group type: COMPARATOR
Intervention: No NGT decompression
Number of subjects: 200
Study 15498060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Number of subjects: 52
Study 15498060 — intervention group
Group type: COMPARATOR
Intervention: 5 mL sub-Tenon's anaesthetic (0.5% bupivacaine/2% lidocaine in a 50:50 mixture)
Number of subjects: 52
Study 11574361 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 8
Study 11574361 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 8
Study 9439539 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated falciparum malaria patients
Number of subjects: 14
Study 9439539 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 8200219 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms levonorgestrel in combination with 50 micrograms ethinylestradiol
Number of subjects: 12
Study 8200219 — intervention group
Group type: COMPARATOR
Intervention: 250 micrograms norgestimate in combination with 35 micrograms ethinylestradiol
Number of subjects: 12
Study 3300988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine once daily (75 mg/kg/day)
Number of subjects: 30
Study 3300988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine twice daily (75 mg/kg/day)
Number of subjects: 30
Study 3300988 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (50 mg/kg/day in three divided doses)
Number of subjects: 30
Study 31365834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A fortified oil (FO)
Number of subjects: 0
Study 31365834 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified oil (NFO)
Number of subjects: 0
Study 30203327 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapies and combinations
Number of subjects: 0
Study 30203327 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy alone or in combination with an antidepressant
Number of subjects: 0
Study 30203327 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 0
Study 30203327 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-term follow-up
Number of subjects: 0
Study 28732650 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg once a day for 5 years)
Number of subjects: 6120
Study 28732650 — intervention group
Group type: COMPARATOR
Intervention: Sequential tamoxifen (20 mg once a day for 2.5-3.0 years) followed by exemestane for a total duration of 5 years
Number of subjects: 6120
Study 25193796 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting and walking in a low-distraction environment (no-priority condition)
Number of subjects: 32
Study 25193796 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting and walking in a high-distraction environment (real-world setting)
Number of subjects: 32
Study 25193796 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting and walking in laboratory settings (gait-priority and texting-priority conditions)
Number of subjects: 32
Study 25193796 — intervention group
Group type: COMPARATOR
Intervention: Texting and walking in laboratory and real-world settings
Number of subjects: 32
Study 23629558 — intervention group
Group type: EXPERIMENTAL
Intervention: CORFIS
Number of subjects: 486
Study 23629558 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 486
Study 21874936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (SBP)
Number of subjects: 24
Study 21874936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambar (AMB)
Number of subjects: 24
Study 21874936 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite (EXC)
Number of subjects: 24
Study 21874936 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water for 24 hours at 37 degrees C)
Number of subjects: 24
Study 21874936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycled (TC) for 20,000 cycles (5‐55 degrees C)
Number of subjects: 24
Study 19801008 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage without dressing changes
Number of subjects: 16
Study 19801008 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dressing changes
Number of subjects: 16
Study 17100723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40-80 mg daily
Number of subjects: 2102
Study 17100723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 12795643 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐intensive conventional treatment (ICT)
Number of subjects: 54
Study 12795643 — intervention group
Group type: COMPARATOR
Intervention: Insulin‐standard treatment (ST)
Number of subjects: 54
Study 10725288 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic shocks (70, 120, 150, 170 J)
Number of subjects: 165
Study 10725288 — intervention group
Group type: COMPARATOR
Intervention: Damped sine wave monophasic shocks (100, 200, 300, 360 J)
Number of subjects: 165
Study 10725288 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic shocks
Number of subjects: 165
Study 10725288 — intervention group
Group type: COMPARATOR
Intervention: Damped sine wave monophasic shocks
Number of subjects: 165
Study 10725288 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 165
Study 10725288 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic impedance
Number of subjects: 165
Study 10725288 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of atrial fibrillation
Number of subjects: 165
Study 8933299 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face prescribing discussion visits led by a pharmaceutical prescribing adviser (Group 1)
Number of subjects: 66
Study 8933299 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice specific prescribing analysis workbooks (Group 2)
Number of subjects: 66
Study 8933299 — intervention group
Group type: COMPARATOR
Intervention: Self-selected control group (Group 3)
Number of subjects: 66
Study 1414555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (1600 mg/day)
Number of subjects: 96
Study 1414555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3873511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose trimethoprim-sulfamethoxazole
Number of subjects: 203
Study 3873511 — intervention group
Group type: COMPARATOR
Intervention: Ten-day trimethoprim-sulfamethoxazole treatment
Number of subjects: 203
Study 30022331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Dysport® injections (50+50 units)
Number of subjects: 100
Study 30022331 — intervention group
Group type: COMPARATOR
Intervention: Unilateral Dysport® injections (100 units)
Number of subjects: 100